Cochrane · systematic review · CD008305
Chinese herbal medicines for hypercholesterolemia
Liu, ZL, Liu, JP, Zhang, AL, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
4
No studies
8
Included studies
NR
No studies 8 · 57.1%Ungraded 2 · 14.3%Very low 2 · 14.3%Low 2 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Xuezhikang compared to simvastatin for hypercholesterolemia
Population: patients with hypercholesterolemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular events ‐ not reported Xuezhikang vs simvastatin | no estimate extracted | NR | No studies |
Death from any cause ‐ not reported Xuezhikang vs simvastatin | no estimate extracted | NR | No studies |
Health‐related quality of life ‐ not reported Xuezhikang vs simvastatin | no estimate extracted | NR | No studies |
Serious adverse events Xuezhikang vs simvastatin | no estimate extracted | 0 studies · 703 participants | Ungraded |
Health costs ‐ not reported Xuezhikang vs simvastatin | no estimate extracted | NR | No studies |
LDL‐cholesterol Xuezhikang vs simvastatin | no estimate extracted | 10 studies · 885 participants | Very low Downgraded: inconsistency, indirectness |
HDL‐cholesterol Xuezhikang vs simvastatin | no estimate extracted | 9 studies · 805 participants | Very low Downgraded: inconsistency |
Xuezhikang compared to pravastatin for hypercholesterolemia
Population: patients with hypercholesterolemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular events ‐ not reported Xuezhikang vs pravastatin | no estimate extracted | NR | No studies |
Death from any cause ‐ not reported Xuezhikang vs pravastatin | no estimate extracted | NR | No studies |
Health‐related quality of life ‐ not reported Xuezhikang vs pravastatin | no estimate extracted | NR | No studies |
Serious adverse events Xuezhikang vs pravastatin | no estimate extracted | 0 studies · 312 participants | Ungraded |
Health costs Xuezhikang vs pravastatin | no estimate extracted | NR | No studies |
LDL‐cholesterol Xuezhikang vs pravastatin | no estimate extracted | 3 studies · 307 participants | Low Downgraded: indirectness |
HDL‐cholesterol Xuezhikang vs pravastatin | no estimate extracted | 3 studies · 307 participants | Low Downgraded: indirectness |